Cargando…

Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients

Thalassaemia is one of the commonest inherited genetic disorders world-wide with around 25,000 births of the most severely affected transfusion dependent children annually. Patients with transfusion dependent thalassaemia require regular blood transfusions to maintain life but because of this will d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eziefula, Chinea, Shah, Farrukh T, Anie, Kofi A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188463/ https://www.ncbi.nlm.nih.gov/pubmed/35698633 http://dx.doi.org/10.2147/PPA.S269352

Ejemplares similares

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Effect of drug use calendar on adherence to iron chelation therapy in young thalassemia patients
por: Chawsamtong, Sriwatree, et al.
Publicado: (2022)

Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia
por: Mohamed, Rafaa, et al.
Publicado: (2022)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia
por: Reddy, Paavani S., et al.
Publicado: (2022)

Markers of Renal Complications in Beta Thalassemia Patients with Iron Overload Receiving Chelation Agent Therapy: A Systematic Review
por: Romadhon, Pradana Zaky, et al.
Publicado: (2022)

Thalassemia Intermedia: Chelator or Not?
por: Lee, Yen-Chien, et al.
Publicado: (2022)

Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: Our experience
por: Jethani, Jitendra, et al.
Publicado: (2010)

Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
por: Saliba, Antoine N, et al.
Publicado: (2015)

Optimizing Communication and Adherence to Iron Chelation Therapy From Diagnosis to Treatment in Patients With Myelodysplastic Syndromes
por: Shah, Jayshree, et al.
Publicado: (2016)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Cardiac Function and Iron Chelation in Thalassemia Major and Intermedia: a Review of the Underlying Pathophysiology and Approach to Chelation Management
por: Aessopos, Athanasios, et al.
Publicado: (2009)

Successful chelation in beta-thalassemia major in the 21(st) century
por: Fragodimitri, Christina, et al.
Publicado: (2023)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Comparative Effects of Three Iron Chelation Therapies on the Quality of Life of Greek Patients with Homozygous Transfusion-Dependent Beta-Thalassemia
por: Goulas, Vasilis, et al.
Publicado: (2012)

Prospective changes of cardiac iron and function by MR in pediatric thalassemia major patients treated with different chelators or not chelated
por: Meloni, Antonella, et al.
Publicado: (2015)

Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy
por: Meloni, Antonella, et al.
Publicado: (2022)

Serum ferritin levels and irregular use of iron chelators predict liver iron load in patients with major beta thalassemia: a cross-sectional study
por: Sobhani, Soheila, et al.
Publicado: (2019)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy
por: Zarghamian, Parinaz, et al.
Publicado: (2020)

Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
por: Veríssimo, Monica Pinheiro de Almeida, et al.
Publicado: (2013)

Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
por: Nuzzi, Raffaele, et al.
Publicado: (2021)

Adherence to Iron Chelation Therapy and Its Determinants
por: Sidhu, Sukhmani, et al.
Publicado: (2021)

Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran
por: Seyedifar, Meysam, et al.
Publicado: (2016)

Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis
por: Punzo, Francesca, et al.
Publicado: (2018)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Pathophysiology and treatment of patients with beta-thalassemia – an update
por: Fibach, Eitan, et al.
Publicado: (2017)

Beliefs about chelation among thalassemia patients
por: Trachtenberg, Felicia L, et al.
Publicado: (2012)

Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
por: Origa, Raffaella, et al.
Publicado: (2022)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Beta-thalassemia
por: Galanello, Renzo, et al.
Publicado: (2010)

Renal function in β-thalassemia major patients treated with two different iron-chelation regimes
por: Tanous, Osama, et al.
Publicado: (2021)

Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study
por: Hamed, Enas A, et al.
Publicado: (2010)

Therapeutic potential of silymarin as a natural iron‐chelating agent in β‐thalassemia intermedia
por: Reisi, Nahid, et al.
Publicado: (2022)

On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure
por: Pennell, DJ, et al.
Publicado: (2011)

Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
por: Susanah, Susi, et al.
Publicado: (2020)

Beta-Thalassemia Major and Female Fertility: The Role of Iron and Iron-Induced Oxidative Stress
por: Roussou, Paraskevi, et al.
Publicado: (2013)

A Patient with Beta-Propeller Protein-Associated Neurodegeneration: Treatment with Iron Chelation Therapy
por: Lim, Shen-Yang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8hkgr9vg1o4iccfqp3q9ke6s75